참고문헌
- Attoub S, Hassan AH, Vanhoecke B, et al (2011). Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol, 651, 18-25. https://doi.org/10.1016/j.ejphar.2010.10.063
- Bagli E, Stefaniotou M, Morbidelli L, et al (2004). Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res, 64, 7936-46. https://doi.org/10.1158/0008-5472.CAN-03-3104
- Chen CC, Chu CB, Liu K J, et al (2013). Gene Expression Profiling for Analysis Acquired Oxaliplatin Resistant Factors in Human Gastric Carcinoma TSGH-S3 Cells: the Role of IL-6 Signaling and Nrf2/AKR1C Axis Identification. Biochem Pharmacol, 86, 872-87 https://doi.org/10.1016/j.bcp.2013.07.025
- Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst, 86, 1517-24. https://doi.org/10.1093/jnci/86.20.1517
- Conseil G, RG Deeley, Cole SP (2005). Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics, 15, 523-33. https://doi.org/10.1097/01.fpc.0000167333.38528.ec
- DeNicola GM, Karreth FA, Humpton TJ, et al (2011). Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106-9. https://doi.org/10.1038/nature10189
- Gao AM, Ke ZP, Wang JN, et al (2013). Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis, 34, 1806-14. https://doi.org/10.1093/carcin/bgt108
- Hu X F, Yao J, Gao SG, et al (2013). Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev, 14, 5231-5. https://doi.org/10.7314/APJCP.2013.14.9.5231
- Itoh K, Mimura J, Yamamoto M (2010). Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal, 13, 1665-78. https://doi.org/10.1089/ars.2010.3222
- Jeong WS, M Jun, A N. Kong (2006). Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal, 8, 99-106. https://doi.org/10.1089/ars.2006.8.99
- Konstantinopoulos PA, Spentzos D, Fountzilas E, et al (2011). Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res, 71, 5081-9. https://doi.org/10.1158/0008-5472.CAN-10-4668
- Kwak MK, Kensler TW (2010). Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol, 244, 66-76. https://doi.org/10.1016/j.taap.2009.08.028
- Lin CW, Wu MJ, Liu IY, Su JD, Yen JH (2010). Neurotrophic and cytoprotective action of luteolin in PC12 cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J Agric Food Chem, 58, 4477-86. https://doi.org/10.1021/jf904061x
- Lin Y, Shi R, Wang X, Shen HM (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8, 634-46. https://doi.org/10.2174/156800908786241050
- Magesh S, Chen Y, Hu L (2012). Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev, 32, 687-726. https://doi.org/10.1002/med.21257
- McMahon M, Itoh K, Yamamoto M, et al (2001). The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res, 61, 3299-307.
- Niture SK, Jaiswal AK (2012). Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem, 287, 9873-86. https://doi.org/10.1074/jbc.M111.312694
- O'Connell M J, Walworth NC, Carr AM (2000). The G2-phase DNA-damage checkpoint. Trends Cell Biol, 10, 296-303. https://doi.org/10.1016/S0962-8924(00)01773-6
- Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52. https://doi.org/10.7314/APJCP.2013.14.10.5543
- Shim G S, Manandhar S, Shin DH, Kim TH, Kwak MK (2009). Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med, 47, 1619-31. https://doi.org/10.1016/j.freeradbiomed.2009.09.006
- Sun GB, Sun X, Wang M, et al (2012). Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol, 265, 229-40. https://doi.org/10.1016/j.taap.2012.10.002
- Tang X, Wang H, Fan L, et al (2011). Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med, 50, 1599-609. https://doi.org/10.1016/j.freeradbiomed.2011.03.008
- Wakabayashi N, Slocum SL, Skoko JJ, et al (2010). When NRF2 talks, who's listening? Antioxid Redox Signal, 13, 1649-63. https://doi.org/10.1089/ars.2010.3216
- Wang JH, Du JP, Zhang YH, et al (2011). Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol, 17, 3986-93. https://doi.org/10.3748/wjg.v17.i35.3986
- Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT (2010). Activation of the NRF2 signaling pathway by coppermediated redox cycling of para- and ortho-hydroquinones. Chem Biol, 17, 75-85. https://doi.org/10.1016/j.chembiol.2009.12.013
- Wruck CJ, Claussen M, Fuhrmann G, et al (2007). Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl, 72, 57-67. https://doi.org/10.1007/978-3-211-73574-9_9
- Yoo NJ, Kim YR, Lee SH (2010). Expression of NRF2, a cytoprotective protein, in gastric carcinomas. APMIS, 118, 613-4.
피인용 문헌
- Association Between the (GT)n Polymorphism of the HO-1 Gene Promoter Region and Cancer Risk: a Meta-analysis vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4617
- Luteolin-loaded Phytosomes Sensitize Human Breast Carcinoma MDA-MB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5311
- Luteolin, a Bioflavonoid Inhibits Colorectal Cancer through Modulation of Multiple Signaling Pathways: A Review vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5501
- Role of the Nrf2 signaling system in health and disease vol.86, pp.5, 2014, https://doi.org/10.1111/cge.12474
- Comparative study of anti-angiogenic activities of luteolin, lectin and lupeol biomolecules vol.13, pp.1, 2015, https://doi.org/10.1186/s12967-015-0665-z
- Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells vol.37, pp.2, 2016, https://doi.org/10.3892/or.2016.5336
- Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia vol.6, pp.2, 2017, https://doi.org/10.3390/antiox6020027
- Luteolin, a novel p90 ribosomal S6 kinase inhibitor, suppresses proliferation and migration in leukemia cells vol.13, pp.3, 2017, https://doi.org/10.3892/ol.2017.5597
- Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion vol.11, pp.1, 2018, https://doi.org/10.1186/s13048-018-0468-y
- Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer pp.20457634, 2018, https://doi.org/10.1002/cam4.1769
- Transcription Factors Contribute to Differential Expression in Cellular Pathways in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma vol.10, pp.4, 2018, https://doi.org/10.1007/s12539-018-0300-9